Latest news with #Natco
News18
3 days ago
- Business
- News18
Donald Trump Says Pharma Tariffs 'Coming Soon'; Indian Drug Stocks Fall Up To 4%
Last Updated: US Pharma Tariffs: Granules India becomes the top loser falling up to 4%, while Aurobindo, Natco and Lupic was down 3% each. US President Donald Trump on June 17 said tariffs on the pharmaceutical sector are 'coming soon". Following comments, which Trump made while speaking to reporters on board the Air Force One, India's pharma stocks declined up to 4%. The Nifty Pharma index declined as much as 2.5% following the Trump comments. Granules India became the top loser falling up to 4%, while Aurobindo, Natco and Lupic was down 3% each. This isn't the first warning — back in April, after imposing reciprocal tariffs on 60 countries (excluding pharma at the time), Trump had hinted that pharma tariffs would come in at 'never seen before" levels and were under active review. 'Pharma tariffs are going to come in at levels you haven't really seen before. We are looking at pharmaceuticals as a separate category. We will be announcing that sometime in the near future, and not too distant future. It's under review right now," Trump had said back in April. The US Commerce Department is currently investigating pharma imports under Section 232, which evaluates the impact of imports on national security. If such tariffs are imposed and companies are unable to pass on the cost, analysts at Citi estimate Indian firms with high exposure to the US generics market could see a 9%-12% one-time hit to their Ebitda.
Business Upturn
5 days ago
- Business
- Business Upturn
Natco Pharma shares dip 2% after company receives one observation from US FDA following Mekaguda API facility inspection
By Aman Shukla Published on June 16, 2025, 09:33 IST Natco Pharma shares fell 2% in early trade after the company announced that the U.S. Food and Drug Administration (US FDA) concluded a routine inspection at its API (Active Pharmaceutical Ingredients) facility in Mekaguda, Hyderabad, with one observation. As of 9:32 AM, the shares were trading 2.59% lower at Rs 889.10. The inspection was carried out over five days, from June 9 to June 13, 2025. In an exchange filing, Natco stated that it received a single Form 483 observation, which it described as procedural in nature. The company expressed confidence in addressing the issue promptly and thoroughly. 'The observation is procedural in nature, and the company is confident of addressing it comprehensively,' Natco said in a statement, reaffirming its commitment to maintaining high compliance standards. The Mekaguda facility plays a key role in Natco's API production for global markets. The company reiterated its focus on adhering to current Good Manufacturing Practices (cGMP) and continuing the supply of high-quality pharmaceutical products. Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. Author or Business Upturn is not liable for any losses arising from the use of this information. Ahmedabad Plane Crash Aman Shukla is a post-graduate in mass communication . A media enthusiast who has a strong hold on communication ,content writing and copy writing. Aman is currently working as journalist at
